Groklaw - Digging for Truth

	When you want to know more...

Home
Archives
Site Map
Search
About Groklaw
Awards
Legal Research
Timelines

ApplevSamsung
ApplevSamsung p.2
ArchiveExplorer
Autozone
Bilski
Cases
Cast: Lawyers
Comes v. MS
Contracts/Documents
Courts
DRM
Gordon v MS
GPL
Grokdoc
HTML How To
IPI v RH
IV v. Google
Legal Docs
Lodsys
MS Litigations
MSvB&N
News Picks
Novell v. MS
Novell-MS Deal
ODF/OOXML
OOXML Appeals
OraclevGoogle
Patents
ProjectMonterey
Psystar
Quote Database
Red Hat v SCO
Salus Book
SCEA v Hotz
SCO Appeals
SCO Bankruptcy
SCO Financials
SCO Overview
SCO v IBM
SCO v Novell
SCO:Soup2Nuts
SCOsource
Sean Daly
Software Patents
Switch to Linux
Transcripts
Unix Books

Gear

Groklaw Gear

You won't find me on Facebook

Donate

No Legal Advice

The information on Groklaw is not intended to constitute legal advice. While Mark is a lawyer and he has asked other lawyers and law students to contribute articles, all of these articles are offered to help educate, not to provide specific legal advice. They are not your lawyers.

Here's Groklaw's comments policy.

What's New

STORIES
No new stories

COMMENTS last 48 hrs
No new comments

Sponsors

Hosting:

On servers donated to ibiblio by AMD.

Webmaster

Well... sorta | 354 comments | Create New Account

Comments belong to whoever posts them. Please notify us of inappropriate comments.

Well... sorta

Authored by: Anonymous on Sunday, November 25 2012 @ 10:45 AM EST

Some truth to this. Given a choice between testing for very
expensive and slightly effective and inexpensive and
effective, companies do make the revenue maximizing choice.
An academic did experience an amazing amount of drug company
blowback when he found that antibiotics treated most ulcers.

But...drug trials are not paid for by academia -- too much
cost. Neither is a lot of drug development. The reality is
that academia just does not have the money. We have done an
amazing job of making drugs too expensive to test.
Admittedly, if patents did not exist, we would find an
alternative funding mechanism that probably would be more in
line with govt incentives (cost reduction)...so this could
be good. OTOH, there are obvious non-patent-related way to
avoid ballooning coats...

--Erwin

[ Reply to This | Parent | # ]

Well... sorta - research example: - Authored by: kattemann on Monday, November 26 2012 @ 07:29 AM EST
- Well... sorta - research example: - Authored by: Anonymous on Monday, November 26 2012 @ 03:17 PM EST
  - Thalidomide - Authored by: Wol on Monday, November 26 2012 @ 04:13 PM EST
    - Thalidomide - Authored by: Anonymous on Monday, November 26 2012 @ 07:21 PM EST

Groklaw © Copyright 2003-2013 Pamela Jones.
All trademarks and copyrights on this page are owned by their respective owners.
Comments are owned by the individual posters.

PJ's articles are licensed under a Creative Commons License. ( Details )